AstraZeneca set to showcase the latest in respiratory science at the 2019 American Thoracic Society (ATS) International Conference



We aim to transform the treatment of respiratory disease with our growing portfolio of inhaled and biologic medicines, along with scientific research targeting the underlying causes of the diseases. We look forward to joining clinicians, researchers and scientists at the 2019 American Thoracic Society (ATS) International Conference to share the latest in respiratory science advancements.


The story of life with severe asthma


Affecting as many as an estimated 34 million people worldwide, severe asthma is a distinct form of asthma that can seriously impact the lives of those living with it. Award-winning documentary filmmaker, Michelle Coomber, shines a light on the realities of living with severe asthma and the opportunities to improve care for patients around the world. We stand with the asthma community to call for increased recognition of the burden of severe asthma. Watch, share, stand with us.









Aiming for disease modification in Respiratory


Our research ambition is to modify, and ultimately cure, respiratory disease. We believe we can do so by addressing the underlying biological drivers of the disease, through our expanded toolbox of drug modalities that go beyond the more traditional small molecules and monoclonal antibodies.

We believe this could allow us to target any novel biology we uncover, and to access targets in the body that were previously seen as hard-to-reach.









Our strategic research involves understanding biologic drivers through four mechanistic and complimentary approaches in chronic lung disease. We investigate what might be the best delivery routes for our drug modalities whether that be systemic or inhaled treatments.








Supporting changes in respiratory clinical care





Pushing the boundaries to deliver innovative solutions

How can AstraZeneca make a difference? Hear more from the people at AstraZeneca who contribute to our commitment to respiratory disease, and our ambition to reframe respiratory care. Our 40-year heritage in respiratory science is just the beginning of our story.





Maria Belvisi

Senior Vice President and Head of Research and Early Development, RIA, R&D BioPharmaceuticals

Tom Keith-Roach

Senior Vice President, Respiratory, Therapeutic Area

Rene van der Merwe

Vice President, Clinical Respiratory



Join Us. Be at the Forefront of Respiratory Health.

Within Respiratory at AstraZeneca, we’re driven by innovation and our commitment to make a real-life difference in patients’ lives. That difference starts with you. As one of Science Magazine’s 2018 Top Employer, we need people like you who share our passion for science and determination to meet patients’ needs around the world.



To be on the leading edge of science and driving that and making these things a reality is just an amazing experience.

Mark White Global Medicines Leader



 

Veeva ID: Z4-16875

Date of next review: May 2020